METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Clinical trials for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation 'Seed' device takes on Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has come back or spread. It tests a special device placed directly into the tumor that gives off a unique type of radiation (alpha rays) combined with an immunotherapy drug called pembrolizumab. The goal is to see i…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New combo therapy aims to shrink tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs—cabozantinib and nivolumab—in people with advanced melanoma or head and neck cancer that has stopped responding to other treatments. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain tumor biomarkers can predi…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New hope for head and neck cancer: cetuximab after failed immunotherapy
Disease control Recruiting nowThis study is for people with head and neck cancer that has come back or spread. It tests whether the drug cetuximab, given alone, can shrink tumors or slow the disease in patients who no longer benefit from immunotherapy. About 38 adults will take part, and the main goal is to s…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 03:33 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
Cholesterol drug boosts immunotherapy against tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding a common cholesterol-lowering drug (lovastatin) to an immunotherapy (pembrolizumab) can help shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has not responded to prior treatments will rece…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New drug combo aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis phase 3 study tests whether adding ficlatuzumab to standard cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer or keep their cancer from growing. About 410 adults with confirmed disease and at least one measurable tumor will be …
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo therapy aims to outsmart tough head and neck cancers
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer than pembrolizumab alone. The trial enrolls about 158 adults whose cancer has returned or spread and no longer responds to platinum chemot…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo attack on head and neck cancer shows promise in early trial
Disease control Recruiting nowThis early-phase study tests whether combining a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has come back or spread. About 24 adults with limited metastatic disease…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with an immunotherapy drug (pembrolizumab), for head and neck cancer that has returned or spread. The study aims to find the safest dose and check for side effects in 40 adul…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Triple therapy aims to reignite immune attack on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests whether combining three treatments—modified natural killer cells (PD-L1 t-haNK), an immune-boosting protein (Anktiva), and a targeted antibody (cetuximab)—can shrink tumors in people with advanced head and neck cancer that has come back or spread. About 25 adults…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo aims to shrink head and neck tumors in First-Line trial
Disease control Recruiting nowThis study tests whether adding ficerafusp alfa to the standard immunotherapy pembrolizumab helps shrink tumors or extend life in people with PD-L1-positive head and neck cancer that has come back or spread. About 650 adults will receive either the combination or a placebo plus p…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New scan could spot hidden head and neck cancers, reducing unnecessary biopsies
Diagnosis Recruiting nowThis early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, used with PET/CT scans, to see if it can safely and more accurately detect head and neck cancers that standard scans may miss. About 25 adults with squamous cell carcinoma of the head and neck will rec…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 22, 2026 13:54 UTC
-
New scan could spot hidden cancer spread in head and neck patients
Diagnosis Recruiting nowThis study tests a new imaging drug called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new imaging agent…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated May 18, 2026 12:06 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 03:37 UTC
-
Cancer patients may soon get infusions at home, cutting travel and stress
Symptom relief Recruiting nowThis study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 26, 2026 03:34 UTC
-
Remote hearing tests could save cancer Patients' ears
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or online can help more head and neck cancer patients get their hearing checked during treatment. Chemotherapy and radiation can cause hearing loss, but many patients skip follow-up tests. The goal is to see if easi…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC